Adverse event totals18

The totals the trial posted for each group.

1 to 18 of 18

Total	Group	Affected	At risk
Total, all-cause mortality	Vyvanse 20 mg
Total, all-cause mortality	Vyvanse 30 mg
Total, all-cause mortality	Vyvanse 40mg
Total, all-cause mortality	Vyvanse 50 mg
Total, all-cause mortality	Vyvanse 60 mg
Total, all-cause mortality	Vyvanse 70mg
Total, other adverse events	Vyvanse 20 mg	11	27
Total, other adverse events	Vyvanse 30 mg	12	22
Total, other adverse events	Vyvanse 40mg	12	19
Total, other adverse events	Vyvanse 50 mg	5	12
Total, other adverse events	Vyvanse 60 mg	4	6
Total, other adverse events	Vyvanse 70mg	1	2
Total, serious adverse events	Vyvanse 20 mg	0	27
Total, serious adverse events	Vyvanse 30 mg	0	22
Total, serious adverse events	Vyvanse 40mg	0	19
Total, serious adverse events	Vyvanse 50 mg	0	12
Total, serious adverse events	Vyvanse 60 mg	0	6
Total, serious adverse events	Vyvanse 70mg	0	2

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01816074/event-totals